



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 41/00, A61P 35/00		A2	(11) International Publication Number: WO 00/38715
			(43) International Publication Date: 6 July 2000 (06.07.00)
<p>(21) International Application Number: PCT/US99/30621</p> <p>(22) International Filing Date: 22 December 1999 (22.12.99)</p> <p>(30) Priority Data: 60/113,786 23 December 1998 (23.12.98) US</p> <p>(71) Applicant (<i>for all designated States except US</i>): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): MCKEARN, John, P. [US/US]; 18612 Babler Meadows Drive, Glencoe, MO 63038 (US). GORDON, Gary [US/US]; 3282 University Avenue, Highland, IL 60035 (US). CUNNINGHAM, James, J. [CA/US]; 3733 North Bell Avenue, Chicago, IL 60618 (US). GATELY, Stephen, T. [CA/US]; 357 E. Shady Pines Court, Palatine, IL 60067-8800 (US). KOKI, Alane, T. [US/US]; 6689 Highway 185, Beaufort, MO 63013 (US). MASFERRER, Jaime, L. [CL/US]; 1213 Blairshire, Ballwin, MO 63011 (US).</p> <p>(74) Agents: KEANE, J. Timothy et al.; G.D. Searle & Co., Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680-5110 (US).</p>			<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>
<p>(54) Title: METHOD OF USING AN INTEGRIN ANTAGONIST AND RADIATION THERAPY AS COMBINATION THERAPY IN THE TREATMENT OF NEOPLASIA</p> <p>(57) Abstract</p> <p>The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	MN	Mongolia	TR	Turkey
BG	Bulgaria	HU	Hungary	MR	Mauritania	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MW	Malawi	UA	Ukraine
BR	Brazil	IL	Israel	MX	Mexico	UG	Uganda
BY	Belarus	IS	Iceland	NE	Niger	US	United States of America
CA	Canada	IT	Italy	NL	Netherlands	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NO	Norway	VN	Viet Nam
CG	Congo	KE	Kenya	NZ	New Zealand	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	PL	Poland	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PT	Portugal		
CM	Cameroon	KR	Republic of Korea	RO	Romania		
CN	China	KZ	Kazakhstan	RU	Russian Federation		
CU	Cuba	LC	Saint Lucia	SD	Sudan		
CZ	Czech Republic	LI	Liechtenstein	SE	Sweden		
DE	Germany	LK	Sri Lanka	SG	Singapore		
DK	Denmark	LR	Liberia				
EE	Estonia						

**METHOD OF USING AN INTEGRIN ANTAGONIST AND RADIATION
THERAPY AS COMBINATION THERAPY IN THE TREATMENT OF
NEOPLASIA**

5

Field of the Invention

The present invention relates to a combination of radiation therapy and an integrin antagonist for treatment of neoplasia disorders. More specifically, this invention relates to the use of integrin antagonists in combination 10 with radiation therapy for treating cancer.

Background of the Invention

A neoplasm, or tumor, is an abnormal, unregulated, and disorganized proliferation of cell growth. A 15 neoplasm is malignant, or cancerous, if it has properties of destructive growth, invasiveness and metastasis. Invasiveness refers to the local spread of a neoplasm by infiltration or destruction of surrounding tissue, typically breaking through the basal laminas 20 that define the boundaries of the tissues, thereby often entering the body's circulatory system. Metastasis typically refers to the dissemination of tumor cells by lymphatics or blood vessels. Metastasis also refers to the migration of tumor cells by direct extension through 25 serous cavities, or subarachnoid or other spaces. Through the process of metastasis, tumor cell migration to other areas of the body establishes neoplasms in areas away from the site of initial appearance.

Cancer is now the second leading cause of death in 30 the United States and over 8,000,000 persons in the United States have been diagnosed with cancer. In 1995, cancer accounted for 23.3% of all deaths in the United States.

Cancer is not fully understood on the molecular level. It is known that exposure of a cell to a carcinogen such as certain viruses, certain chemicals, or radiation, leads to DNA alteration that inactivates a 5 "suppressive" gene or activates an "oncogene".
Suppressive genes are growth regulatory genes, which upon mutation, can no longer control cell growth.
Oncogenes are initially normal genes (called proto-oncogenes) that by mutation or altered context of 10 expression become transforming genes. The products of transforming genes cause inappropriate cell growth. More than twenty different normal cellular genes can become oncogenes by genetic alteration. Transformed cells differ from normal cells in many ways, including cell 15 morphology, cell-to-cell interactions, membrane content, cytoskeletal structure, protein secretion, gene expression and mortality.

Cancer is now primarily treated with one or a combination of three types of therapies: surgery, 20 radiation, and chemotherapy. Surgery involves the bulk removal of diseased tissue. While surgery is sometimes effective in removing tumors located at certain sites, for example, in the breast, colon, and skin, it cannot be used in the treatment of tumors located in other 25 areas, inaccessible to surgeons, nor in the treatment of disseminated neoplastic conditions such as leukemia.

Chemotherapy involves the disruption of cell replication or cell metabolism. It is used most often in the treatment of breast, lung, and testicular cancer.

30 The adverse effects of systemic chemotherapy used in the treatment of neoplastic disease is most feared by patients undergoing treatment for cancer. Of these

adverse effects nausea and vomiting are the most common and severe side effects. Other adverse side effects include cytopenia, infection, cachexia, mucositis in patients receiving high doses of chemotherapy with bone 5 marrow rescue or radiation therapy; alopecia (hair loss); cutaneous complications such as pruritis, urticaria, and angioedema; neurological complications; pulmonary and cardiac complications in patients receiving radiation or chemotherapy; and reproductive 10 and endocrine complications (M. Abeloff, et al., *Alopecia and Cutaneous Complications*, in *Clinical Oncology* 755-56 (Abeloff, ed. 1992)).

Chemotherapy-induced side effects significantly impact the quality of life of the patient and may 15 dramatically influence patient compliance with treatment.

Additionally, adverse side effects associated with chemotherapeutic agents are generally the major dose-limiting toxicity (DLT) in the administration of these 20 drugs. For example, mucositis, is one of the major dose limiting toxicity for several anticancer agents, including the antimetabolite cytotoxic agents 5-FU, methotrexate, and antitumor antibiotics, such as doxorubicin. Many of these chemotherapy-induced side 25 effects if severe, may lead to hospitalization, or require treatment with analgesics for the treatment of pain.

In general, radiation therapy is employed as potentially curative therapy for patients who present 30 with clinically localized disease and are expected to live at least 10 years.

For example, approximately 70% of newly diagnosed prostate cancer patients fall into this category. Approximately 10% of these patients (7% of total patients) undergo radiation therapy. Approximately 80% 5 of patients who have undergone radiation as their primary therapy have disease persistence or develop recurrence or metastasis within five years after treatment. Currently, most of these radiotherapy patients generally do not receive any immediate follow-up therapy. Rather, they are monitored frequently, such as for elevated Prostate Specific Antigen ("PSA"), which is the primary indicator of recurrence or metastasis in prostate cancer.

15 The adverse side effects induced by chemotherapeutic agents and radiation therapy have become of major importance to the clinical management of cancer patients.

Colorectal Cancer

20 Survival from colorectal cancer depends on the stage and grade of the tumor, for example precursor adenomas to metastatic adenocarcinoma. Generally, colorectal cancer can be treated by surgically removing the tumor, but overall survival rates remain between 45 and 60 percent. Colonic excision morbidity rates are 25 fairly low and is generally associated with the anastomosis and not the extent of the removal of the tumor and local tissue. In patients with a high risk of reoccurrence, however, chemotherapy has been incorporated into the treatment regimen in order to 30 improve survival rates.

Tumor metastasis prior to surgery is generally believed to be the cause of surgical intervention

failure and up to one year of chemotherapy is required to kill the non-excised tumor cells. As severe toxicity is associated with the chemotherapeutic agents, only patients at high risk of recurrence are placed on 5 chemotherapy following surgery.

Prostate Cancer

Prostate cancer is now the leading form of cancer among men and the second most frequent cause of death from cancer in men. It is estimated that more than 10 165,000 new cases of prostate cancer were diagnosed in 1993, and more than 35,000 men died from prostate cancer in that year. Additionally, the incidence of prostate cancer has increased by 50% since 1981, and mortality from this disease has continued to increase. Previously, 15 most men died of other illnesses or diseases before dying from their prostate cancer. We now face increasing morbidity from prostate cancer as men live longer and the disease has the opportunity to progress.

Current therapies for prostate cancer focus upon 20 reducing levels of dihydrotestosterone to decrease or prevent growth of prostate cancer. Radiation alone or in combination with surgery and/or chemotherapeutic agents is often used.

In addition to the use of digital rectal 25 examination and transrectal ultrasonography, prostate-specific antigen (PSA) concentration is frequently used in the diagnosis of prostate cancer.

U.S. Pat. No. 4,472,382 discloses treatment of benign prostatic hyperplasia (BPH) with an antiandrogen 30 and certain peptides which act as LH-RH agonists. U.S. Pat. No. 4,596,797 discloses aromatase inhibitors as a method of prophylaxis and/or treatment of prostatic

hyperplasia. U.S. Pat. No. 4,760,053 describes a treatment of certain cancers which combines an LHRH agonist with an antiandrogen and/or an antiestrogen and/or at least one inhibitor of sex steroid biosynthesis. U.S. Pat. No. 4,775,660 discloses a method of treating breast cancer with a combination therapy which may include surgical or chemical prevention of ovarian secretions and administering an antiandrogen and an antiestrogen. U.S. Pat. No. 4,659,695 discloses a method of treatment of prostate cancer in susceptible male animals including humans whose testicular hormonal secretions are blocked by surgical or chemical means, e.g. by use of an LHRH agonist, which comprises administering an antiandrogen, e.g. flutamide, in association with at least one inhibitor of sex steroid biosynthesis, e.g. aminoglutethimide and/or ketoconazole.

Prostate Specific Antigen

One well known prostate cancer marker is Prostate Specific Antigen (PSA). PSA is a protein produced by prostate cells and is frequently present at elevated levels in the blood of men who have prostate cancer. PSA has been shown to correlate with tumor burden, serve as an indicator of metastatic involvement, and provide a parameter for following the response to surgery, irradiation, and androgen replacement therapy in prostate cancer patients. It should be noted that Prostate Specific Antigen (PSA) is a completely different protein from Prostate Specific Membrane Antigen (PSMA). The two proteins have different structures and functions and should not be confused because of their similar nomenclature.

Prostate Specific Membrane Antigen (PSMA)

In 1993, the molecular cloning of a prostate-specific membrane antigen (PSMA) was reported as a potential prostate carcinoma marker and hypothesized to 5 serve as a target for imaging and cytotoxic treatment modalities for prostate cancer. Antibodies against PSMA have been described and examined clinically for diagnosis and treatment of prostate cancer. In particular, Indium-111 labeled PSMA antibodies have been 10 described and examined for diagnosis of prostate cancer and indium-labeled PSMA antibodies have been described and examined for the treatment of prostate cancer.

Pancreas Cancer

Approximately 2% of new cancer cases diagnoses in 15 the United States is pancreatic cancer. Pancreatic cancer is generally classified into two clinical types: 1) adenocarcinoma (metastatic and non-metastatic), and 2) cystic neoplasms (serous cystadenomas, mucinous cystic neoplasms, papillary cystic neoplasms, acinar cell 20 cystadenocarcinoma, cystic choriocarcinoma, cystic teratomas, angiomatic neoplasms).

Ovary Cancer

Celomic epithelial carcinoma accounts for approximately 90% of ovarian cancer cases. Preferred 25 single agents that can be used in combination include: alkylating agents, ifosfamide, cisplatin, carboplatin, taxol, doxorubicin, 5-fluorouracil, methotrexate, mitomycin, hexamethylmelamine, progestins, antiestrogens, prednimustine, dihydroxybusulfan, 30 galactitol, interferon alpha and interferon gamma.

Cancer of the fallopian tube is the least common type of ovarian cancer, accounting for approximately 400

new cancer cases per year in the United States.

Papillary serous adenocarcinoma accounts for approximately 90% of all malignancies of the ovarian tube.

5

Detailed Description of the Invention

Treatment of a neoplasia disorder in a mammal in need of such treatment is provided by methods and combinations using radiation and an integrin antagonist.

10 The method comprises treating a mammal with a therapeutically effective amount of a combination comprising an integrin antagonist and a radiotherapeutic agent. Besides being useful for human treatment, the present invention is also useful for veterinary

15 treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. More preferred animals include horses, dogs, and cats.

20 Integrin antagonist potentiate tumor response to radiation. Thus, integrin antagonists improve the efficacy of radiotherapy.

The methods and combinations of the present invention may be used for the treatment of neoplasia disorders selected from the group consisting of acral lentiginous melanoma, actinic keratoses, adenocarcinoma, adenoid cystic carcinoma, adenomas, adenosarcoma, 25 adenosquamous carcinoma, astrocytic tumors, bartholin gland carcinoma, basal cell carcinoma, bronchial gland carcinomas, capillary, carcinoids, carcinoma, carcinosarcoma, cavernous, cholangiocarcinoma, chondrosarcoma, choriod plexus papilloma/carcinoma, 30 clear cell carcinoma, cystadenoma, endodermal sinus tumor, endometrial hyperplasia, endometrial stromal

sarcoma, endometrioid adenocarcinoma, ependymal,
epitheloid, Ewing's sarcoma, fibrolamellar, focal
nodular hyperplasia, gastrinoma, germ cell tumors,
glioblastoma, glucagonoma, hemangiblastomas,
5 hemangioendothelioma, hemangiomas, hepatic adenoma,
hepatic adenomatosis, hepatocellular carcinoma,
insulinoma, intraepithelial neoplasia, interepithelial
squamous cell neoplasia, invasive squamous cell
carcinoma, large cell carcinoma, leiomyosarcoma, lentigo
10 maligna melanomas, malignant melanoma, malignant
mesothelial tumors, medulloblastoma, medulloepithelioma,
melanoma, meningeal, mesothelial, metastatic carcinoma,
mucoepidermoid carcinoma, neuroblastoma, neuroepithelial
adenocarcinoma nodular melanoma, oat cell carcinoma,
15 oligodendroglial, osteosarcoma, pancreatic polypeptide,
papillary serous adenocarcinoma, pineal cell, pituitary
tumors, plasmacytoma, pseudosarcoma, pulmonary blastoma,
renal cell carcinoma, retinoblastoma, rhabdomyosarcoma,
sarcoma, serous carcinoma, small cell carcinoma, soft
20 tissue carcinomas, somatostatin-secreting tumor,
squamous carcinoma, squamous cell carcinoma,
submesothelial, superficial spreading melanoma,
undifferentiated carcinoma, uveal melanoma, verrucous
carcinoma, vipoma, well differentiated carcinoma, and
25 Wilm's tumor.

The methods and compositions of the present
invention provide one or more benefits. A combination
of an integrin antagonist with radiation therapy of the
present invention are useful in treating neoplasia
30 disorders. Preferably, the integrin antagonist agent or
agents and the radiation therapies of the present
invention is administered in combination at a low dose,

that is, at a dose lower than has been conventionally used in clinical situations for each of the individual components administered alone.

A benefit of lowering the dose of the radiation 5 therapies of the present invention administered to a mammal includes a decrease in the incidence of adverse effects associated with higher dosages.

By lowering the incidence of adverse effects, an improvement in the quality of life of a patient 10 undergoing treatment for cancer is contemplated.

Further benefits of lowering the incidence of adverse effects include an improvement in patient compliance, and a reduction in the number of hospitalizations needed for the treatment of adverse effects.

15 Alternatively, the methods and combination of the present invention can also maximize the therapeutic effect at higher doses.

The phrase "combination therapy" (or "co-therapy") embraces the administration of a integrin antagonist and 20 radiation therapy, and, optionally, an antineoplastic agent, as part of a specific treatment regimen intended to provide a beneficial effect from the co-action of the integrin antagonist and the radiation therapy. The beneficial effect of the combination includes, but is 25 not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of the integrin antagonist and the radiation therapy. Administration of the integrin antagonist and the radiation therapy in combination typically is carried out over a defined time 30 period (usually minutes, hours, days or weeks depending upon the combination selected). "Combination therapy" generally is not intended to encompass the

administration of a integrin antagonist and radiation therapy as part of separate monotherapy regimens that incidentally and arbitrarily result in the combinations of the present invention. "Combination therapy" is

5 intended to embrace administration of integrin antagonist and radiation therapy in a sequential manner, that is, wherein the integrin antagonist and the radiation therapy are administered at different times, as well as administration of the integrin antagonist and

10 radiation therapy in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject concurrently with radiation therapy a single capsule having a fixed ratio of each therapeutic agent

15 or in multiple, single capsules for each therapeutic agent. Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes,

20 and direct absorption through mucous membrane tissues. The therapeutic agents, if more than one, can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination selected may be administered by intravenous

25 injection while the other therapeutic agents of the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or all therapeutic agents may be administered by intravenous injection. The sequence in which the

30 integrin antagonist and radiation therapy are administered is not narrowly critical although radiation therapy typically will follow the administration of the

integrin antagonist. "Combination therapy" also can embrace the administration of the integrin antagonist and radiation therapy as described above in further combination with other biologically active ingredients 5 (such as, but not limited to, an antineoplastic agent) and non-drug therapies (such as, but not limited to, surgery). The radiation treatment of the combination may be conducted at any suitable time so long as a beneficial effect from the co-action of the combination 10 of the integrin antagonist and radiation treatment is achieved. For example, in appropriate cases, the beneficial effect is still achieved even when the radiation treatment is temporally removed from the administration of the integrin antagonist, perhaps by 15 days or even weeks.

The term "pharmaceutically acceptable" is used herein to mean that the modified noun is appropriate for use in a pharmaceutical product. Pharmaceutically acceptable cations include metallic ions and organic 20 ions. More preferred metallic ions include, but are not limited to appropriate alkali metal salts, alkaline earth metal salts and other physiological acceptable metal ions. Exemplary ions include aluminum, calcium, lithium, magnesium, potassium, sodium and zinc in their 25 usual valences. Preferred organic ions include protonated tertiary amines and quaternary ammonium cations, including in part, trimethylamine, diethylamine, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, 30 ethylenediamine, meglumine (N-methylglucamine) and procaine. Exemplary pharmaceutically acceptable acids include without limitation hydrochloric acid,

hydrobromic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, acetic acid, formic acid, tartaric acid, maleic acid, malic acid, citric acid, isocitric acid, succinic acid, lactic acid, gluconic acid, 5 glucuronic acid, pyruvic acid, oxalacetic acid, fumaric acid, propionic acid, aspartic acid, glutamic acid, benzoic acid, and the like.

Also included in the combination of the invention are the isomeric forms and tautomers of the described 10 compounds and the pharmaceutically-acceptable salts thereof. Illustrative pharmaceutically acceptable salts are prepared from formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, 15 glutamic, benzoic, anthranilic, mesylic, stearic, salicylic, p-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, toluenesulfonic, 2-hydroxyethanesulfonic, sulfanilic, 20 cyclohexylaminosulfonic, algenic, β -hydroxybutyric, galactaric and galacturonic acids.

Suitable pharmaceutically-acceptable base addition salts of compounds of the present invention include metallic ion salts and organic ion salts. More preferred 25 metallic ion salts include, but are not limited to appropriate alkali metal (group Ia) salts, alkaline earth metal (group IIa) salts and other physiological acceptable metal ions. Such salts can be made from the ions of aluminum, calcium, lithium, magnesium, potassium, sodium 30 and zinc. Preferred organic salts can be made from tertiary amines and quaternary ammonium salts, including in part, trimethylamine, diethylamine, N,N'-

dibenzylethylenediamine, chlorprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine) and procaine. All of the above salts can be prepared by those skilled in the art by conventional 5 means from the corresponding compound of the present invention.

An integrin antagonist of the present invention can be formulated as a pharmaceutical composition. Such a composition can then be administered orally, 10 parenterally, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration can also involve the use of transdermal 15 administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques. Formulation of drugs is discussed in, for 20 example, Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania; 1975 and Liberman, H.A. and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, N.Y., 1980.

25 Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions can be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile 30 injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable

vehicles and solvents that can be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. Dimethyl acetamide, surfactants including ionic and non-ionic detergents, polyethylene glycols can be used. Mixtures of solvents and wetting agents such as those discussed above are also useful.

Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter, synthetic mono- di- or triglycerides, fatty acids and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.

Solid dosage forms for oral administration can include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per os, a contemplated aromatic sulfone hydroximate inhibitor compound can be admixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then

tableted or encapsulated for convenient administration. Such capsules or tablets can contain a controlled-release formulation as can be provided in a dispersion of active compound in hydroxypropylmethyl cellulose. In 5 the case of capsules, tablets, and pills, the dosage forms can also comprise buffering agents such as sodium citrate, magnesium or calcium carbonate or bicarbonate. Tablets and pills can additionally be prepared with enteric coatings.

10 For therapeutic purposes, formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared from sterile powders or granules having one or 15 more of the carriers or diluents mentioned for use in the formulations for oral administration. A contemplated integrin antagonist compound can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other 20 adjuvants and modes of administration are well and widely known in the pharmaceutical art.

Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, 25 solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions can also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

30 The amount of active ingredient that can be combined with the carrier materials to produce a single

dosage form varies depending upon the mammalian host treated and the particular mode of administration.

The term "treatment" refers to any process, action, application, therapy, or the like, wherein a mammal, 5 including a human being, is subject to medical aid with the object of improving the mammal's condition, directly or indirectly.

The term "inhibition," in the context of neoplasia, tumor growth or tumor cell growth, may be assessed by 10 delayed appearance of primary or secondary tumors, slowed development of primary or secondary tumors, decreased occurrence of primary or secondary tumors, slowed or decreased severity of secondary effects of disease, arrested tumor growth and regression of tumors, 15 among others. In the extreme, complete inhibition, is referred to herein as prevention.

The term "prevention" includes either preventing the onset of clinically evident neoplasia altogether or preventing the onset of a preclinically evident stage of 20 neoplasia in individuals at risk. Also intended to be encompassed by this definition is the prevention of initiation for malignant cells or to arrest or reverse the progression of premalignant cells to malignant cells. This includes prophylactic treatment of those at 25 risk of developing the neoplasia.

Angiogenesis is an attractive therapeutic target because it is a multi-step process that occurs in a specific sequence, thus providing several possible targets for drug action. Examples of agents that 30 interfere with several of these steps include specific integrin antagonists.

The phrase "therapeutically-effective" is intended to qualify the amount of each agent that will achieve the goal of improvement in neoplastic disease severity and the frequency of incidence over treatment of each 5 agent by itself, while avoiding adverse side effects typically associated with alternative therapies.

A "therapeutic effect" relieves to some extent one or more of the symptoms of a neoplasia disorder. In reference to the treatment of a cancer, a therapeutic 10 effect refers to one or more of the following: 1) reduction in the number of cancer cells; 2) reduction in tumor size; 3) inhibition (i.e., slowing to some extent, preferably stopping) of cancer cell infiltration into peripheral organs; 4) inhibition (i.e., slowing to some 15 extent, preferably stopping) of tumor metastasis; 5) inhibition, to some extent, of tumor growth; 6) relieving or reducing to some extent one or more of the symptoms associated with the disorder; and/or 7) relieving or reducing the side effects associated with 20 the administration of anticancer agents.

"Therapeutic effective amount" is intended to qualify the amount required to achieve a therapeutic effect.

The phrases "low dose" or "low dose amount", in 25 characterizing a therapeutically effective amount of the integrin antagonist and the radiation or therapy in the combination therapy, defines a quantity of such therapy, or a range of quantity of such therapy, that is capable of diminishing the neoplastic disease while reducing or 30 avoiding one or more radiation-induced side effects, such as myelosuppression, cardiac toxicity, skin erythema and desquamation, alopecia, inflammation or fibrosis.

The phrase "adjunctive therapy" includes agents such as those, for example, that reduce the toxic effect of anticancer drugs, e.g., bone resorption inhibitors, cardioprotective agents; prevent or reduce the incidence 5 of nausea and vomiting associated with chemotherapy, radiotherapy or operation; or reduce the incidence of infection associated with the administration of myelosuppressive anticancer drugs.

The phrase a "radiotherapeutic agent" refers to the 10 use of electromagnetic or particulate radiation in the treatment of neoplasia. Examples of radiotherapeutic agents are provided in, but not limited to, radiation therapy and is known in the art (Hellman, Principles of Radiation Therapy, Cancer, in Principles and Practice of 15 Oncology, 248-75 (Devita et al., ed., 4th edit., volume 1, 1993)).

The term "clinical tumor" includes neoplasms that are identifiable through clinical screening or diagnostic procedures including, but not limited to, 20 palpation, biopsy, cell proliferation index, endoscopy, mammography, digital mammography, ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), radiography, radionuclide evaluation, CT- or MRI-guided aspiration 25 cytology, and imaging-guided needle biopsy, among others. Such diagnostic techniques are well known to those skilled in the art and are described in Cancer Medicine 4th Edition, Volume One. J.F. Holland, R.C. Bast, D.L. Morton, E. Frei III, D.W. Kufe, and R.R. 30 Weichselbaum (Ed). Williams & Wilkins, Baltimore (1997).

The term "tumor marker" or "tumor biomarker" encompasses a wide variety of molecules with divergent

characteristics that appear in body fluids or tissue in association with a clinical tumor and also includes tumor-associated chromosomal changes. Tumor markers fall primarily into three categories: molecular or cellular markers, 5 chromosomal markers, and serological or serum markers. Molecular and chromosomal markers complement standard parameters used to describe a tumor (i.e. histopathology, grade, tumor size) and are used primarily in refining disease diagnosis and prognosis after clinical 10 manifestation. Serum markers can often be measured many months before clinical tumor detection and are thus useful as an early diagnostic test, in patient monitoring, and in therapy evaluation.

Molecular Tumor Markers

15 Molecular markers of cancer are products of cancer cells or molecular changes that take place in cells because of activation of cell division or inhibition of apoptosis. Expression of these markers can predict a cell's malignant potential. Because cellular markers are not secreted, tumor 20 tissue samples are generally required for their detection. Non-limiting examples of molecular tumor markers that can be used in the present invention are listed in Table No. 1, below.

Table No. 1. Non-limiting Examples of Molecular Tumor
25 Markers

Tumor	Marker
Breast	p53
Breast, Ovarian	ErbB-2/Her-2
Breast	S phase and ploidy
Breast	pS2
Breast	MDR2

Breast	urokinase plasminogen activator
Breast, Colon, Lung	myc family

Chromosomal Tumor Markers

Somatic mutations and chromosomal aberrations have been associated with a variety of tumors. Since the 5 identification of the Philadelphia Chromosome by Nowell and Hungerford, a wide effort to identify tumor-specific chromosomal alterations has ensued. Chromosomal cancer markers, like cellular markers, are can be used in the diagnosis and prognosis of cancer. In addition to the 10 diagnostic and prognostic implications of chromosomal alterations, it is hypothesized that germ-line mutations can be used to predict the likelihood that a particular person will develop a given type of tumor. Non-limiting examples of chromosomal tumor markers that can be used 15 in the present invention are listed in Table No. 2, below.

Table No. 2. Non-limiting Examples of Chromosomal Tumor Markers

Tumor	Marker
Breast	1p36 loss
Breast	6q24-27 loss
Breast	11q22-23 loss
Breast	11q13 amplification
Breast	TP53 mutation
Colon	Gain of chromosome 13
Colon	Deletion of short arm of chromosome 1
Lung	Loss of 3p
Lung	Loss of 13q

Lung	Loss of 17p
Lung	Loss of 9p

Serological Tumor Markers

Serum markers including soluble antigens, enzymes and hormones comprise a third category of tumor markers.

5 Monitoring serum tumor marker concentrations during therapy provides an early indication of tumor recurrence and of therapy efficacy. Serum markers are advantageous for patient surveillance compared to chromosomal and cellular markers because serum samples are more easily obtainable
10 than tissue samples, and because serum assays can be performed serially and more rapidly. Serum tumor markers can be used to determine appropriate therapeutic doses within individual patients. For example, the efficacy of a combination regimen consisting of chemotherapeutic and
15 antiangiogenic agents can be measured by monitoring the relevant serum cancer marker levels. Moreover, an efficacious therapy dose can be achieved by modulating the therapeutic dose so as to keep the particular serum tumor marker concentration stable or within the reference range,
20 which may vary depending upon the indication. The amount of therapy can then be modulated specifically for each patient so as to minimize side effects while still maintaining stable, reference range tumor marker levels.
Table No. 3 provides non-limiting examples of serological
25 tumor markers that can be used in the present invention.

Table No. 3. Non-limiting Examples of Serum Tumor
 Markers

Cancer Type	Marker
Germ Cell Tumors	α -fetoprotein (AFP)

Germ Cell Tumors	human chorionic gonadotrophin (hCG)
Germ Cell Tumors	placental alkaline phosphatase (PLAP)
Germ Cell Tumors	lactate dehydrogenase (LDH)
Prostate	prostate specific antigen (PSA)
Breast	carcinoembryonic antigen (CEA)
Breast	MUC-1 antigen (CA15-3)
Breast	tissue polypeptide antigen (TPA)
Breast	tissue polypeptide specific antigen (TPS)
Breast	CYFRA 21.1
Breast	soluble erb-B-2
Ovarian	CA125
Ovarian	OVX1
Ovarian	cancer antigen CA72-4
Ovarian	TPA
Ovarian	TPS
Gastrointestinal	CD44v6
Gastrointestinal	CEA
Gastrointestinal	cancer antigen CA19-9
Gastrointestinal	NCC-ST-439 antigen (Dukes C)
Gastrointestinal	cancer antigen CA242
Gastrointestinal	soluble erb-B-2
Gastrointestinal	cancer antigen CA195
Gastrointestinal	TPA
Gastrointestinal	YKL-40

Gastrointestinal	TPS
Esophageal	CYFRA 21-1
Esophageal	TPA
Esophageal	TPS
Esophageal	cancer antigen CA19-9
Gastric Cancer	CEA
Gastric Cancer	cancer antigen CA19-9
Gastric Cancer	cancer antigen CA72-4
Lung	neruon specific enolase (NSE)
Lung	CEA
\Lung	CYFRA 21-1
Lung	cancer antigen CA 125
Lung	TPA
Lung	squamous cell carcinoma antigen (SCC)
Pancreatic cancer	ca19-9
Pancreatic cancer	ca50
Pancreatic cancer	ca119
Pancreatic cancer	ca125
Pancreatic cancer	CEA
Pancreatic cancer	
Renal Cancer	CD44v6
Renal Cancer	E-cadherin
Renal Cancer	PCNA (proliferating cell nuclear antigen)

Examples

Germ Cell Cancers

5 Non-limiting examples of tumor markers useful in the present invention for the detection of germ cell

cancers include, but are not limited to, a-fetoprotein (AFP), human chorionic gonadotrophin (hCG) and its beta subunit (hCGb), lactate dehydrogenase (LDH), and placental alkaline phosphatase (PLAP).

5 AFP has an upper reference limit of approximately -10 kU/L after the first year of life and may be elevated in germ cell tumors, hepatocellular carcinoma and also in gastric, colon, biliary, pancreatic and lung cancers. AFP serum half life is approximately five days
10 after orchidectomy. According to EGTM recommendations, AFP serum levels less than 1,000 kU/L correlate with a good prognosis, AFP levels between 1,000 and 10,000 kU/L, inclusive, correlate with intermediate prognosis, and AFP levels greater than 10,000 U/L correlate with a
15 poor prognosis.

 HCG is synthesized in the placenta and is also produced by malignant cells. Serum hCG concentrations may be increased in pancreatic adenocarcinomas, islet cell tumors, tumors of the small and large bowel,
20 hepatoma, stomach, lung, ovaries, breast and kidney. Because some tumors only hCGb, measurement of both hCG and hCGb is recommended. Normally, serum hCG in men and pre-menopausal women is as high as -5 U/L while post-menopausal women have levels up to -10 U/L. Serum half
25 life of hCG ranges from 16-24 hours. According to the EGTM, hCG serum levels under 5000 U/L correlate with a good prognosis, levels between 5000 and 50000 U/L, inclusively correlate with an intermediate prognosis, and hCG serum levels greater than 50000 U/L correlate
30 with a poor prognosis. Further, normal hCG half lives correlate with good prognosis while prolonged half lives correlate with poor prognosis.

LDH is an enzyme expressed in cardiac and skeletal muscle as well as in other organs. The LDH-1 isoenzyme is most commonly found in testicular germ cell tumors but can also occur in a variety of benign conditions 5 such as skeletal muscle disease and myocardial infarction. Total LDH is used to measure independent prognostic value in patients with advanced germ cell tumors. LDH levels less than 1.5 x the reference range are associated with a good prognosis, levels between 1.5 10 and 10 x the reference range, inclusive, are associated with an intermediate prognosis, and levels more than 10 x the reference range are associated with a poor prognosis.

PLAP is a enzyme of alkaline phosphatase normally 15 expressed by placental syncytiotrophoblasts. Elevated serum concentrations of PLAP are found in seminomas, non-seminomatous tumors, and ovarian tumors, and may also provide a marker for testicular tumors. PLAP has a normal half life after surgical resection of between 0.6 20 and 2.8 days.

Prostate Cancer

A nonlimiting example of a tumor marker useful in the present invention for the detection of prostate cancer is prostate specific antigen (PSA). PSA is a 25 glycoprotein that is almost exclusively produced in the prostate. In human serum, uncomplexed f-PSA and a complex of f-PSA with a1-antichymotrypsin make up total PSA (t-PSA). T-PSA is useful in determining prognosis in patients that are not currently undergoing anti-androgen 30 treatment. Rising t-PSA levels via serial measurement indicate the presence of residual disease.

Breast Cancer

Non-limiting examples of serum tumor markers useful in the present invention for the detection of breast cancer include, but is not limited to carcinoembryonic antigen (CEA) and MUC-1 (CA 15.3). Serum CEA and CA15.3 levels are elevated in patients with node involvement compared to patients without node involvement, and in patients with larger tumors compared to smaller tumors. Normal range cutoff points (upper limit) are 5-10 mg/L for CEA and 35-60 u/ml for CA15.3. Additional specificity (99.3%) is gained by confirming serum levels with two serial increases of more than 15%.

Ovarian Cancer

A non-limiting example of a tumor marker useful in the present invention for the detection of ovarian cancer is CA125. Normally, women have serum CA125 levels between 0-35 kU/L; 99% of post-menopausal women have levels below 20 kU/L. Serum concentration of CA125 after chemotherapy is a strong predictor of outcome as elevated CA125 levels are found in roughly 80% of all patients with epithelial ovarian cancer. Further, prolonged CA125 half-life or a less than 7-fold decrease during early treatment is also a predictor of poor disease prognosis.

Gastrointestinal Cancers

A non-limiting example of a tumor marker useful in the present invention for the detection of colon cancer is carcinoembryonic antigen (CEA). CEA is a glycoprotein produced during embryonal and fetal development and has a high sensitivity for advanced carcinomas including those of the colon, breast, stomach and lung. High pre- or postoperative concentrations (>2.5 ng/ml) of CEA are associated with worse prognosis than are low

concentrations. Further, some studies in the literature report that slow rising CEA levels indicates local recurrence while rapidly increasing levels suggests hepatic metastasis.

5 Lung Cancer

Examples of serum markers useful in the present invention to monitor lung cancer therapy include, but are not limited to, CEA, cytokeratin 19 fragments (CYFRA 21-1), and Neuron Specific Enolase (NSE).

10 NSE is a glycolytic isoenzyme of enolase produced in central and peripheral neurons and malignant tumors of neuroectodermal origin. At diagnosis, NSE concentrations greater than 25 ng/mL are suggestive of malignancy and lung cancer while concentrations greater than 100 ng/mL are 15 suggestive of small cell lung cancer.

20 CYFRA 21-1 is a tumor marker test which uses two specific monoclonal antibodies against a cytokeratin 19 fragment. At diagnosis, CYFRA 21-1 concentrations greater than 10 ng/mL are suggestive of malignancy while concentrations greater than 30 ng/mL are suggestive of lung cancer.

25 Accordingly, dosing of the integrin antagonist and radiation therapy may be determined and adjusted based on measurement of tumor markers in body fluids or tissues, particularly based on tumor markers in serum. For example, a decrease in serum marker level relative to baseline serum marker prior to administration of the integrin antagonist and radiation therapy indicates a decrease in cancer-associated changes and provides a 30 correlation with inhibition of the cancer. In one embodiment, therefore, the method of the present invention comprises administering the integrin antagonist and

radiation therapy at doses that in combination result in a decrease in one or more tumor markers, particularly a decrease in one or more serum tumor markers, in the mammal relative to baseline tumor marker levels.

5 Similarly, decreasing tumor marker concentrations or serum half lives after administration of the combination indicates a good prognosis, while tumor marker concentrations which decline slowly and do not reach the normal reference range predict residual tumor
10 and poor prognosis. Further, during follow-up therapy, increases in tumor marker concentration predicts recurrent disease many months before clinical manifestation.

In addition to the above examples, Table No. 4, below,
15 lists several references, hereby individually incorporated by reference herein, that describe tumor markers and their use in detecting and monitoring tumor growth and progression.

20 Table No. 4. Tumor marker references.

European Group on Tumor Markers Publications
Committee. Consensus Recommendations. Anticancer
Research 19: 2785-2820 (1999)

Human Cytogenetic Cancer Markers. Sandra R. Wolman and
Stewart Sell (eds.). Totowa, New Jersey: Humana Press.
1997

Cellular Markers of Cancer. Carleton Garrett and
Stewart Sell (eds.). Totowa, New Jersey: Human Press.
1995

The phrase "integrin antagonist" includes agents that impair endothelial cell adhesion via the various integrins. Integrin antagonists induce improperly proliferating endothelial cells to die, by interfering 5 with molecules that blood vessel cells use to bridge between a parent blood vessel and a tumor.

Adhesion forces are critical for many normal physiological functions. Disruptions in these forces, through alterations in cell adhesion factors, are 10 implicated in a variety of disorders, including cancer, stroke, osteoporosis, restenosis, and rheumatoid arthritis (A. F. Horwitz, *Scientific American*, 276:(5): 68-75, 1997).

Integrins are a large family of cell surface 15 glycoproteins which mediate cell adhesion and play central roles in many adhesion phenomena. Integrins are heterodimers composed of noncovalently linked alpha and beta polypeptide subunits. Currently eleven different alpha subunits have been identified and six different 20 beta subunits have been identified. The various alpha subunits can combine with various beta subunits to form distinct integrins.

One integrin known as $\alpha_v\beta_3$ (or the vitronectin receptor) is normally associated with endothelial cells 25 and smooth muscle cells. $\alpha_v\beta_3$ integrins can promote the formation of blood vessels (angiogenesis) in tumors. These vessels nourish the tumors and provide access routes into the bloodstream for metastatic cells.

The $\alpha_v\beta_3$ integrin is also known to play a role in 30 various other disease states or conditions including tumor metastasis, solid tumor growth (neoplasia),

osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, angiogenesis, including tumor angiogenesis, retinopathy, arthritis, including rheumatoid arthritis, periodontal disease, psoriasis, and smooth muscle cell 5. migration (e.g. restenosis).

Tumor cell invasion occurs by a three step process:
1) tumor cell attachment to extracellular matrix;
2) proteolytic dissolution of the matrix; and 3)
movement of the cells through the dissolved barrier.
10 This process can occur repeatedly and can result in metastases at sites distant from the original tumor.

The $\alpha_v\beta_3$ integrin and a variety of other α_v -
containing integrins bind to a number of Arg-Gly-Asp
(RGD) containing matrix macromolecules. Compounds
15 containing the RGD sequence mimic extracellular matrix
ligands and bind to cell surface receptors. Fibronectin
and vitronectin are among the major binding partners of
 $\alpha_v\beta_3$ integrin. Other proteins and peptides also bind
the $\alpha_v\beta_3$ ligand. These include the disintegrins (M.
20 Pfaff et al., *Cell Adhes. Commun.* 2(6): 491-501, 1994),
peptides derived from phage display libraries (Healy,
J.M. et al., *Protein Pept. Lett.* 3(1): 23-30, 1996;
Hart, S.L. et al., *J. Biol. Chem.* 269(17): 12468-12474,
1994) and small cyclic RGD peptides (M. Pfaff et al., *J.*
25 *Biol. Chem.*, 269(32): 20233-20238, 1994). The
monoclonal antibody LM609 is also an $\alpha_v\beta_3$ integrin
antagonist (D.A. Cheresh et al., *J. Biol. Chem.*,
262(36): 17703-17711, 1987).

$\alpha_v\beta_3$ inhibitors are being developed as potential
30 anti-cancer agents. Compounds that impair endothelial

cell adhesion via the $\alpha_v\beta_3$ integrin induce improperly proliferating endothelial cells to die.

The $\alpha_v\beta_3$ integrin has been shown to play a role in melanoma cell invasion (Seftor et al., *Proc. Natl. Acad. Sci. USA*, 89: 1557-1561, 1992). The $\alpha_v\beta_3$ integrin expressed on human melanoma cells has also been shown to promote a survival signal, protecting the cells from apoptosis (Montgomery et al., *Proc. Natl. Acad. Sci. USA*, 91: 8856-8860, 1994).

10 Mediation of the tumor cell metastatic pathway by interference with the $\alpha_v\beta_3$ integrin cell adhesion receptor to impede tumor metastasis would be beneficial. Antagonists of $\alpha_v\beta_3$ have been shown to provide a therapeutic approach for the treatment of neoplasia

15 (inhibition of solid tumor growth) because systemic administration of $\alpha_v\beta_3$ antagonists causes dramatic regression of various histologically distinct human tumors (Brooks et al., *Cell*, 79: 1157-1164, 1994).

The adhesion receptor identified as integrin $\alpha_v\beta_3$ is a marker of angiogenic blood vessels in chick and man. This receptor plays a critical role in angiogenesis or neovascularization. Angiogenesis is characterized by the invasion, migration and proliferation of smooth muscle and endothelial cells by 25 new blood vessels. Antagonists of $\alpha_v\beta_3$ inhibit this process by selectively promoting apoptosis of cells in the neovasculature. The growth of new blood vessels, also contributes to pathological conditions such as diabetic retinopathy (Adonis et al., *Amer. J. Ophthal.*,

118: 445-450, 1994) and rheumatoid arthritis (Peacock et al., *J. Exp. Med.*, 175: 1135-1138, 1992). Therefore, $\alpha_v\beta_3$ antagonists can be useful therapeutic targets for treating such conditions associated with 5 neovascularization (Brooks et al., *Science*, 264: 569-571, 1994).

The $\alpha_v\beta_3$ cell surface receptor is also the major integrin on osteoclasts responsible for the attachment to the matrix of bone. Osteoclasts cause bone 10 resorption and when such bone resorbing activity exceeds bone forming activity, osteoporosis (a loss of bone) results, which leads to an increased number of bone fractures, incapacitation and increased mortality.

Antagonists of $\alpha_v\beta_3$ have been shown to be potent 15 inhibitors of osteoclastic activity both *in vitro* (Sato et al., *J. Cell. Biol.*, 111: 1713-1723, 1990) and *in vivo* (Fisher et al., *Endocrinology*, 132: 1411-1413, 1993). Antagonism of $\alpha_v\beta_3$ leads to decreased bone 20 resorption and therefore assists in restoring a normal balance of bone forming and resorbing activity. Thus it would be beneficial to provide antagonists of osteoclast $\alpha_v\beta_3$ which are effective inhibitors of bone resorption and therefore are useful in the treatment or prevention of osteoporosis.

25 PCT Int. Appl. WO 97/08145 by Sikorski et al., discloses meta-guanidine, urea, thiourea or azacyclic amino benzoic acid derivatives as highly specific $\alpha_v\beta_3$ integrin antagonists.

PCT Int. Appl. WO 96/00574 A1 960111 by Cousins,

R.D. et. al., describe preparation of 3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine and -2-benzazepine derivatives and analogs as vitronectin receptor antagonists.

5 PCT Int. Appl. WO 97/23480 A1 970703 by Jadhav, P.K. et. al. describe annelated pyrazoles as novel integrin receptor antagonists. Novel heterocycles including 3-[1-[3-(imidazolin-2-ylamino)propyl]indazol-5-ylcarbonylamino]-2-(benzyl oxycarbonylamino)propionic acid, which are useful as antagonists of the avb3 integrin and related cell surface adhesive protein receptors.

10 PCT Int. Appl. WO 97/26250 A1 970724 by Hartman, G.D. et al., describe the preparation of arginine 15 dipeptide mimics as integrin receptor antagonists. Selected compounds were shown to bind to human integrin avb3 with EIB <1000 nM and claimed as compounds, useful for inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood 20 platelets.

25 PCT Int. Appl. WO 97/23451 by Diefenbach, B. et. al. describe a series of tyrosine-derivatives used as alpha v-integrin inhibitors for treating tumors, osteoporosis, osteolytic disorder and for suppressing angiogenesis.

30 PCT Int. Appl. WO 96/16983 A1 960606. by Vuori, K. and Ruoslahti, E. describe cooperative combinations of avb3 integrin ligand and second ligand contained within a matrix, and use in wound healing and tissue regeneration. The compounds contain a ligand for the avb3 integrin and a ligand for the insulin receptor, the

PDGF receptor, the IL-4 receptor, or the IGF receptor, combined in a biodegradable polymeric (e.g. hyaluronic acid) matrix.

PCT Int. Appl. WO 97/10507 A1 970320 by Ruoslahti, 5 E; and Pasqualini, R. describe peptides that home to a selected organ or tissue *in vivo*, and methods of identifying them. A brain-homing peptide, nine amino acid residues long, for example, directs red blood cells to the brain. Also described is use of *in vivo* panning 10 to identify peptides homing to a breast tumor or a melanoma.

PCT Int. Appl. WO 96/01653 A1 960125 by Thorpe, Philip E.; Edgington, Thomas S. describes bifunctional ligands for specific tumor inhibition by blood 15 coagulation in tumor vasculature. The disclosed bispecific binding ligands bind through a first binding region to a disease-related target cell, e.g. a tumor cell or tumor vasculature; the second region has coagulation-promoting activity or is a binding region 20 for a coagulation factor. The disclosed bispecific binding ligand may be a bispecific (monoclonal) antibody, or the two ligands may be connected by a (selectively cleavable) covalent bond, a chemical linking agent, an avidin-biotin linkage, and the like. 25 The target of the first binding region can be a cytokine-inducible component, and the cytokine can be released in response to a leukocyte-activating antibody; this may be a bispecific antibody which crosslinks activated leukocytes with tumor cells.

30 Nonlimiting examples of integrin antagonists that may be used in the present invention are identified in Table 5, below.

Table No. 5. Examples of Integrin antagonists

Compound	Trade/ Research Name	Mode of Action	Reference	Dosage
2 (S)- Benzenesulfonamido)-3-[4-[2-(3,4,5,6-tetrahydropyrimidin-2-ylamino)ethoxy]benzamido]propionic acid	L-748415	Vitronectin antagonist		
	Merk KGaA Compound I25			
Ethyl beta-[[2-[[[3-[(3,4,5,6-tetrahydro-2H-azepin-7-yl)amino]phenyl]carbonylamino]acetyl]-amino]pyridine-3-propanoic acid		Vitronectin antagonist	WO 97/08145	
O-[9,10-dimethoxy-1,2,3,4,5,6-hexahydro-4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)hydrazono]-8-benz(e)azulenyl]-N-[(phenylmethoxy)carbonyl]-DL-homoserine 2,3-dihydroxypropyl ester		Vitronectin antagonist	WO 97/34865	
(2S)-Benzoylcarbonyl		Vitronectin antagonist	EP 796855	

Compound	Trade/ Research Name	Mode of Action	Reference	Dosage
amino-3-[2-((4S)-(3-(4,5-dihydro-1H-imidazol-2-ylamino)-propyl)-2,5-dioxo-imidazolidin-1-yl)-acetylamino]-propionate				
	S-836	Vitronectin antagonist; Angiogenesis inhibitor; solid tumors		
(S)-2-[7-[N-(Benzimidazol-2-ylmethyl)-N-methylcarbamoyl]-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepin-2-yl]acetic acid	SB-223245	Vitronectin antagonist; Angiogenesis inhibitor		
	SD-983	Vitronectin antagonist; Angiogenesis inhibitor		
Isoxaoline derivatives		Vitronectin receptor antagonist	WO 96/37492	0.001-10 mg/kg/day; 0.01-0.5 (pref. 0.01-0.1) mg/kg/ day intra-nasally
(2S)-Benzoylcarbonyl amino-3-[2-((4S)-(3-(4,5-dihydro-1H-		Vitronectin antagonist	EP 796855	

Compound	Trade/ Research Name	Mode of Action	Reference	Dosage
imidazol-2-ylamino)-propyl)-2,5-dioxo-imidazolidin-1-yl)-acetylamino]-propionate				
Benzazulene derivatives; O-[9,10-dimethoxy-1,2,3,4,5,6-hexahydro-4-[(1,4,5,6-tetrahydro-2-pyrimidinyl)hydrazono]-8-benz(e)azzulenyl]-N-[(phenylmethoxy)carbonyl]-DL-homoserine 2,3-dihydroxypropyl ester		Vitronectin antagonist	WO 97/34865	
Immunoglobulin G, (human-mouse monoclonal c7E3 clone p7E3VHhC gamma 4 Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3VkhCk light chain-	abcix-imab; ReoPro	GPIIb IIIa receptor antagonist; Vitronectin antagonist		Recomended dosage: Intra-venous bolus of 0.25 mg/kg, followed by 10 µg/min for 12 hrs.
Arg-Gly-Asp-D-phe-Val	cRGDFV penta-peptide	Apoptosis agonist; Vitronectin antagonist		

Compound	Trade/ Research Name	Mode of Action	Reference	Dosage
	vitro- nectin antag- onist	Vitronectin antagonist		Orally active

Further examples of integrin antagonists can be found in the following documents:

WO 98/07432	WO 98/16227	WO 97/36862	WO 97/36861
WO 97/36860	WO 9736859	WO 97/36858	US 5639765
WO 97/08145	US 5639765	WO 98/22500	WO 98/20897
WO 98/18764	WO 98/14192	WO 98/08840	WO 98/04913
WO 97/48395	WO 9744333	WO 98/00395	WO 97/41102
WO 97/34865	WO 97/39028	WO 97/37655	WO 97/33887
EP 796855	WO 97/26250	WO 97/24124	WO 97/24122
WO 97/24336	WO 97/24119	WO 97/23480	WO 97/23451
EP 765660	WO 97/14716	EP 77/1818	WO 97/01540
WO 96/37492	EP 741133	US 5565449	WO 96/26190
EP 727425	US 5627197	DE 4439846	EP 711770
EP 710657	WO 96/06087	WO 96/00730	WO 96/00574
WO 95/23811	US 5464855	WO 95/28426	JP 07242645
JP 07206860	EP 645376	WO 95/07712	WO 95/00544
AU 9464771	EP 614664	WO 94/21607	WO 94/15936
JP 06128289	WO 9411739	WO 93/08174	EP 537654
EP 529858	US 5229366	WO 92/07870	WO 92/00995
EP 381033	WO 98/08518	US 5721210	EP 820991
EP 820988	WO 97/48444	WO 97/41844	WO 97/45447
WO 97/45137	US 5686570	US 5686568	US 5686571
US 5686569	US 5686567	US 5686566	WO 97/41149
DE 19613933	WO 97/35615	WO 97/25031	US 5639726
WO 97/18838	WO 97/11718	US 5612311	EP 77/0622

WO 97/08203	WO 97/06791	WO 97/03094	WO 96/40781
WO 96/40250	US 5536814	US 5510332	WO 96/07734
WO 96/05304	WO 96/00581	WO 95/34641	WO 95/30438
DE 4415310	EP 668278	EP 656348	DE 4336758
EP 623615	DE 4310643	AU 9459185	WO 94/01152
CA 2120303	EP 632053	EP 618225	WO 94/18981
WO 94/13310	JP 06116289	WO 94/05310	EP 58/9181
EP 589181	US 5491129	WO 93/25218	WO 93/20229
US 5225531	EP 570352	EP 570352	WO 92/09200
WO 91/15515	EP 445796	WO 91/07977	EP 410767
US 5061693	EP 384362	US 5663297	EP 372486
US 5039805	WO 9003983	WO 89/05155	DE 19548798
DE 19626701	DE 19653645	DE 9653646	DE 19653647
DE 19654483	DE 4439846	EP 683173	EP 537654
EP 645376	EP 0710657	EP 727425	EP 741133
EP 771565	EP 0846702	EP 853084	JP 07285992
JP 08337523	JP 09169742	JP 9235239	JP 09316000
JP 10045587	JP 08183752	JP 183788	US 5574026
WO 95/14714	WO 9525543	WO 95/28426	WO 95/32710
WP 96/06087	WO 96/26190	WO 96/32945	WO 97/12625
WO 97/15666	WO 97/16197	WO 97/21726	WO 97/22596
WO 97/23625	WO 97/24336	WO 98/25892	WO 98/25601
WO 97/26258	WO 97/33576	WO 98/00144	WO 98/00395
WO 98/03573	WO 98/08518	WO 98/08840	WO 98/10795
WO 98/11089	WO 98/11223	WO 98/12226	WO 98/13071
WO 98/13350	WO 98/13354	WO 98/14192	WO 98/15278
WO 98/15574	WO 98/18460	WO 98/18461	WO 98/18764
WO 98/21230	WO 98/23608	WO 98/23613	

The following individual references each hereby incorporated by reference herein, describe various

integrin antagonists suitable for use in the invention described herein, and processes for their manufacture:

WO 98/07432	WO 98/16227	WO 97/36862	WO 97/36861
WO 97/36860	WO 97/36859	WO 97/36858	US 5639765
WO 97/08145	US 5639765	WO 98/22500	WO 98/20897
WO 98/18764	WO 98/14192	WO 98/08840	WO 98/04913
WO 97/48395	WO 97/44333	WO 98/00395	WO 97/41102
WO 97/34865	WO 97/39028	WO 97/37655	WO 97/33887
EP 79/6855	WO 97/26250	WO 97/24124	WO 97/24122
WO 97/24336	WO 97/24119	WO 97/23480	WO 97/23451
EP 76/5660	WO 97/14716	EP 771818	WO 97/01540
WO 96/37492	EP 74/1133	US 5565449	WO 96/26190
EP 72/7425	US 5627197	DE 4439846	EP 711770
EP 71/0657	WO 96/06087	WO 96/00730	WO 96/00574
WO 95/23811	US 5464855	WO 95/28426	JP 07242645
JP 07/206860	EP 64/5376	WO 95/07712	WO 95/00544
AU 94/64771	EP 61/4664	WO 94/21607	WO 94/15936
JP 06/128289	WO 94/11739	WO 93/08174	EP 537654
EP 52/9858	US 52/29366	WO 92/07870	WO 92/00995
EP 38/1033	WO 98/08518	US 572,210	EP 820991
EP 82/0988	WO 97/48444	WO 97/41844	WO 97/45447
WO 97/45137	US 5686570	US 5686568	US 5686571
US 5686569	US 5686567	US 5686566	WO 97/41149
DE 19/613933	WO 97/35615	WO 97/25031	US 5639726
WO 97/18838	WO 97/11718	US 5612311	EP 770622
WO 97/08203	WO 97/06791	WO 97/03094	WO 96/40781
WO 96/40250	US 5536814	US 5510332	WO 96/07734
WO 96/05304	WO 96/00581	WO 95/34641	WO 95/30438
DE 44/15310	EP 66/8278	EP 656348	DE 4336758
EP 62/3615	DE 43/10643	AU 94/59185	NO 94/01152
CA 21/20303	EP 63/2053	EP 618225	WO 94/18981

WO 94/13310	JP 06/116289	WO 94/05310	EP 58/9181
EP 58/9181	US 5491129	WO 93/25218	WO 93/20229
U.S. 5225531	EP 570352	EP 57/0352	WO 92/09200
WO 91/15515	EP 445796	WO 91/07977	EP 410767
US 5061693	EP 384362	US 5,63297	EP 37/2486
US 5039805	WO 90/03983	WO 89/05155	DE 19548798
DE 19/626701	DE 19653645	DE 19653646	DE 19653647
DE 19/654483	DE 4439846	EP 683173	EP 537654
EP 0/645376	EP 0710657	EP 727425	EP 741133
EP 0/771565	EP 0846702	EP 853084	JP 07285992
JP 08/337523	JP 09169742	JP 09235239	JP 09316000
JP 10/045587	JP 08183752	JP 08183788	US 5574026
WO 95/14714	WO 95/25543	WO 95/28426	WO 95/32710
WP 96/06087	WO 96/26190	WO 96/32945	WO 97/12625
WO 97/15666	WO 97/16197	WO 97/21726	WO 97/22596
WO 97/23625	WO 97/24336	WO 98/25892	WO 98/25601
WO 97/26258	WO 97/33576	WO 98/00144	WO 98/00395
WO 98/03573	WO 98/08518	WO 98/08840	WO 98/10795
WO 98/11089	WO 98/11223	WO 98/12226	WO 98/13071
WO 98/13350	WO 98/13354	WO 98/14192	WO 98/15278
WO 98/15574	WO 98/18460	WO 98/18461	WO 98/18764
WO 98/21230	WO 98/23608	WO 98/23613	

The following individual references each hereby incorporated by reference herein, describe additional 5 integrin antagonists suitable for use in the invention described herein, and processes for their manufacture:

WO 99/50249	WO 99/45927	WO 99/44994	US 5955572
US 59552341	WO 99/38849	WO 99/37683	WO 99/37621
WO 99/33798	EP 928793	US 5925655	US 5919792

WO 99/32457	WO 99/31099	US 5912234	WO 99/31061
WO 99/31061	WO 99/30713	WO 99/30709	WO 99/26945
WO 99/15508	WO 99/15507	WO 99/15506	WO 99/15178
WO 99/15170	WO 99/11626	WO 99/06049	WO 99/05107
US 5852210	US 5843906	WO 98/54217	US 5840961
WO 98/43962	US 5773646	US 5773644	WO 98/33919
WO 98/31359	WO 98/30542	EP 854145	EP 854140
EP 853084	US 5773412	US 5766591	US 5760028
US 5759996	WO 98/15278	US 5741796	WO 98/10795
WO 97/08145			

The Vitaxin used in the therapeutic combinations of the present invention can be prepared in the manner set forth in WO 98/33,919.

5 Some Preferred integrin antagonists that may be used in the present invention are listed in the following references hereby each individually incorporated by reference, herein:


U.S. Patent No. 5,773,644; U.S. Patent No. 5,773,646;

10 Patent Application Serial No. U.S. 092/89,140; U.S. Patent No. 5,852,210; U.S. Patent No. 5,843,906; U.S. Patent Application Serial No. 091/41,547; U.S. Patent No. 5,952,381; U.S. Patent Application No. 092/88,742; Patent Application Serial No. U.S. 600/03,277; Patent

15 Application Serial No. U.S. 087/13,555; Patent Application Serial No. U.S. 092/15,229; Patent Application Serial No. U.S. 090/34,758; Patent Application Serial No. U.S. 092/61,822; WO 98/33919.

More preferred integrin antagonists that may be used in the present invention include, but are not limited to


5 I1)



(3R)-N-[(5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine;

10

I2)




15

(3R)-N-[(1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine;

20


I3)



(3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)- β -alanine;

5


I4)



10

(3R)-N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)- β -alanine;

I5)




15

(3R)-N-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)- β -alanine;


20

I6)



(3R)-N-[3-
[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-
bromo-5-chloro-2-hydroxyphenyl)-*b*-alanine;


5 I7)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-
hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-
(3-bromo-5-chloro-2-hydroxyphenyl)-*b*-alanine;

10

I8)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-
hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-
(3,5-dichloro-2-hydroxyphenyl)-*b*-alanine;

15


I9)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-*b*-alanine;

5


I10)



(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-*b*-alanine;

10


I11)



15

b-[3-[[3-[[4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]sulfonyl]amino]phenyl]-3,5-difluorobenzenepropanoic acid;


I12)



20


3,5-difluoro-b-[3-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]methyl]phenyl]benzenepropanoic acid;

I13)



5


I14)



10

(2E)-3-[3-ethyl-4-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]phenyl]-2-propenoic acid;

I15)




15

(2E)-3-[3-[2-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]-2-oxoethoxy]phenyl]-2-propenoic acid;

I16)


20



(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid;

5


I17)



10

(2S)-7-[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;

I18)




15

(2S)-2,3,4,5-tetrahydro-4-methyl-7-[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;

20


I19)



(bR)-b-[[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid;


5

I20)




10

I21)




15

I22)



20


I23)



I24) Vitaxin antibody (Ixsys);


I25) Merck KGaA EMD-121974, cyclo[RGDf-N(Me)V-];

I26)




5

I27)




I28)




10

I29)




I30)




I31)

5




I32)




10

I33)




I34)

15




I35)




5


136)



137)




138)




10

139)




I40)




5

I41)




I42)



10


I43)



Still more preferred integrin antagonists include

15 but are not limited to

I16)




5

(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid;

10


I17)



15

(2S)-7-[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;


I18)



20

(2S)-2,3,4,5-tetrahydro-4-methyl-7-[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;


I19)



(bR)-b-[[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid;

5

I23)




10

I24) Vitaxin antibody(Ixsys);


15

I25) Merck KGaA EMD-121974, cyclo[RGDF-N(Me)V-];

I27)




I34)




I35)

5



I36)

10 Dosage of integrin antagonists

Dosage levels of integrin antagonists on the order of about 0.1 mg to about 10,000 mg of the active ingredient compound are useful in the treatment of the above conditions, with preferred levels of about 1.0 mg to 15 about 1,000 mg. The amount of active ingredient that may be combined with other anticancer agents to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.

It is understood, however, that a specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, 5 general health, sex, diet, time of administration, rate of excretion, drug combination, and the severity of the particular disease being treated and form of administration.

Treatment dosages generally may be titrated to 10 optimize safety and efficacy. Typically, dosage-effect relationships from in vitro initially can provide useful guidance on the proper doses for patient administration. Studies in animal models also generally may be used for guidance regarding effective dosages for treatment of 15 cancers in accordance with the present invention. In terms of treatment protocols, it should be appreciated that the dosage to be administered will depend on several factors, including the particular agent that is administered, the route administered, the condition of 20 the particular patient, etc. Generally speaking, one will desire to administer an amount of the compound that is effective to achieve a serum level commensurate with the concentrations found to be effective in vitro. Thus, where a compound is found to demonstrate in vitro 25 activity at, e.g., 10 μ M, one will desire to administer an amount of the drug that is effective to provide about a 10 μ M concentration in vivo. Determination of these parameters are well within the skill of the art.

These considerations, as well as effective 30 formulations and administration procedures are well known in the art and are described in standard textbooks.

Administration Regimen

Any effective treatment regimen can be utilized and readily determined and repeated as necessary to effect treatment. In clinical practice, the compositions 5 containing a integrin antagonist alone or in combination with other therapeutic agents are administered in specific cycles until a response is obtained.

For patients who initially present without advanced or metastatic cancer, an integrin antagonist in 10 combination with radiation therapy, is used as a continuous post-treatment therapy in patients at risk for recurrence or metastasis (for example, in adenocarcinoma of the prostate, risk for metastasis is based upon high PSA, high Gleason's score, locally 15 extensive disease, and/or pathological evidence of tumor invasion in the surgical specimen). The goal in these patients is to inhibit the growth of potentially metastatic cells from the primary tumor during surgery and inhibit the growth of tumor cells from undetectable 20 residual primary tumor.

For patients who initially present with advanced or metastatic cancer, an integrin antagonist in combination with radiation therapy of the present invention is used as a continuous supplement to, or 25 possible replacement for hormonal ablation. The goal in these patients is to slow or prevent tumor cell growth from both the untreated primary tumor and from the existing metastatic lesions.

Illustrations

The following discussion highlights some agents in this respect, which are illustrative, not limitative. A wide variety of other effective agents also may be used.

5

Colorectal Cancer

The preferred combination therapy for the treatment of colorectal cancer is surgery, followed by a regimen of one or more chemotherapeutic agents, cycled over a 10 one year time period. In the treatment of colorectal cancer, radiation alone or in combination with surgery and/or chemotherapeutic agents is often used. Preferred chemotherapeutic agents include fluorouracil, and Levamisole. Preferably, fluorouracil and Levamisole are 15 used in combination.

Prostate Cancer

Current therapies for prostate cancer focus upon reducing levels of dihydrotestosterone to decrease or 20 prevent growth of prostate cancer. Radiation alone or in combination with surgery and/or chemotherapeutic agents is often used.

Pancreas Cancer

Preferred combinations of therapy for the treatment 25 of non-metastatic adenocarcinoma include the use of preoperative biliary tract decompression (patients presenting with obstructive jaundice); surgical resection, including standard resection, extended or 30 radial resection and distal pancreatectomy (tumors of body and tail); adjuvant radiation; and chemotherapy.

For the treatment of metastatic adenocarcinoma, the

preferred chemotherapy consists of 5-fluorouracil, followed weekly cisplatin therapy.

Lung Cancer

5 In many countries including Japan, Europe and America, the number of patients with lung cancer is fairly large and continues to increase year after year and is the most frequent cause of cancer death in both men and women. Although there are many potential causes 10 for lung cancer, tobacco use, and particularly cigarette smoking, is the most important. Additionally, etiologic factors such as exposure to asbestos, especially in smokers, or radon are contributory factors. Also occupational hazards such as exposure to uranium have 15 been identified as an important factor. Finally, genetic factors have also been identified as another factor that increase the risk of cancer.

Lung cancers can be histologically classified into non-small cell lung cancers (e.g. squamous cell 20 carcinoma (epidermoid), adenocarcinoma, large cell carcinoma (large cell anaplastic), etc.) and small cell lung cancer (oat cell). Non-small cell lung cancer (NSCLC) has different biological properties and responses to chemotherapeutics from those of small cell 25 lung cancer (SCLC). Thus, chemotherapeutic formulas and radiation therapy are different between these two types of lung cancer.

Non-Small Cell Lung Cancer

30 Where the location of the non-small cell lung cancer tumor can be easily excised (stage I and II disease) surgery is the first line of therapy and offers

a relatively good chance for a cure. However, in more advanced disease (stage IIIa and greater), where the tumor has extended to tissue beyond the bronchopulmonary lymph nodes, surgery may not lead to complete excision 5 of the tumor. In such cases, the patient's chance for a cure by surgery alone is greatly diminished. Where surgery will not provide complete removal of the NSCLC tumor, other types of therapies must be utilized.

Today radiation therapy is the standard treatment 10 to control unresectable or inoperable NSCLC. Improved results have been seen when radiation therapy has been combined with chemotherapy, but gains have been modest and the search continues for improved methods of combining modalities.

15 Radiation therapy is based on the principle that high-dose radiation delivered to a target area will result in the death of reproductive cells in both tumor and normal tissues. The radiation dosage regimen is generally defined in terms of radiation absorbed dose 20 (rad), time and fractionation, and must be carefully defined by the oncologist. The amount of radiation a patient receives will depend on various consideration but the two most important considerations are the location of the tumor in relation to other critical 25 structures or organs of the body, and the extent to which the tumor has spread. A preferred course of treatment for a patient undergoing radiation therapy for NSCLC will be a treatment schedule over a 5 to 6 week period, with a total dose of 50 to 60 Gy administered to 30 the patient in a single daily fraction of 1.8 to 2.0 Gy, 5 days a week. A Gy is an abbreviation for Gray and refers to 100 rad of dose.

However, as NSCLC is a systemic disease, and radiation therapy is a local modality, radiation therapy as a single line of therapy is unlikely to provide a cure for NSCLC, at least for those tumors that have 5 metastasized distantly outside the zone of treatment.

Thus, the use of radiation therapy with other modality regimens have important beneficial effects for the treatment of NSCLC.

Generally, radiation therapy has been combined 10 temporally with chemotherapy to improve the outcome of treatment. There are various terms to describe the temporal relationship of administering radiation therapy and chemotherapy, and the following examples are the preferred treatment regimens and are generally known by 15 those skilled in the art and are provided for illustration only and are not intended to limit the use of other combinations. "Sequential" radiation therapy and chemotherapy refers to the administration of chemotherapy and radiation therapy separately in time in 20 order to allow the separate administration of either chemotherapy or radiation therapy. "Concomitant" radiation therapy and chemotherapy refers to the administration of chemotherapy and radiation therapy on the same day. Finally, "alternating" radiation therapy 25 and chemotherapy refers to the administration of radiation therapy on the days in which chemotherapy would not have been administered if it was given alone.

It is reported that advanced non-small cell lung cancers do not respond favorably to single-agent 30 chemotherapy and useful therapies for advanced inoperable cancers have been limited. (J. Clin. Oncol. 1992, 10, 829-838).

Japanese Patent Kokai 5-163293 refers to 16-membered-ring macrolide antibiotics as a drug delivery carrier capable of transporting anthonoracycline-type anticancer drugs into the lungs for the treatment of 5 lung cancers. However, the macrolide antibiotics specified herein are disclosed to be only a drug carrier, and there is no reference to the therapeutic use of macrolides against non-small cell lung cancers.

WO 93/18652 refers to the effectiveness of the 10 specified 16-membered-ring macrolides such as baflomycin, etc. in treating non-small cell lung cancers, but they have not yet been clinically practicable.

Pharmacology, vol. 41, pp. 177-183 (1990) describes 15 that a long-term use of erythromycin increases productions of interleukins 1, 2 and 4, all of which contribute to host immune responses, but there is no reference to the effect of this drug on non-small cell lung cancers.

20 Tetragenesis, Carcinogenesis, and Mutagenesis, vol. 10, pp. 477-501 (1990) describes that some of antimicrobial drugs can be used as an anticancer agent, but does not refer to their application to non-small cell lung cancers.

25 In addition, interleukins are known to have an antitumor effect, but have not been reported to be effective against non-small cell lung cancers.

Any 14 - or 15-membered-ring macrolides have not been reported to be effective against non-small cell 30 lung cancers.

However, several chemotherapeutic agents have been shown to be efficacious against NSCLC. Preferred

chemotherapeutic agents against NSCLC include etoposide, carboplatin, methotrexate, 5-fluorouracil, epirubicin, doxorubicin, and cyclophosphamide. The most preferred chemotherapeutic agents active against NSCLC include 5 cisplatin, ifosfamide, mitomycin C, epirubicin, vinblastine, and vindesine.

Other agents that are under investigation for use against NSCLC include: camptothecins, a topoisomerase 1 inhibitor; navelbine (vinorelbine), a microtubule 10 assembly inhibitor; taxol, inhibitor of normal mitotic activity; gemcitabine, a deoxycytidine analogue; fotemustine, a nitrosourea compound; and edatrexate, a antifol.

The overall and complete response rates for NSCLC 15 has been shown to increase with use of combination chemotherapy as compared to single-agent treatment. Haskel, Chest. 1991, 99: 1325; Bakowsk, Cancer Treat. Rev. 1983, 10:159; Joss, Cancer Treat. Rev. 1984, 11: 205.

20

Small Cell Lung Cancer

Approximately 15 to 20 percent of all cases of lung cancer reported worldwide is small cell lung cancer (SCLC). (Ihde, Cancer 1984, 54, 2722). Currently, 25 treatment of SCLC incorporates multi-modal therapy, including chemotherapy, radiation therapy and surgery. Response rates of localized or disseminated SCLC remain high to systemic chemotherapy, however, persistence of the primary tumor and persistence of the tumor in the 30 associated lymph nodes has led to the integration of several therapeutic modalities in the treatment of SCLC.

The most preferred chemotherapeutic agents against SCLC include vincristine, cisplatin, carboplatin, cyclophosphamide, epirubicin (high dose), etoposide (VP-16) I.V., etoposide (VP-16) oral, ifosfamide, teniposide 5 (VM-26), and doxorubicin. Preferred single-agents chemotherapeutic agents include BCNU (carmustine), vindesine, hexamethylmelamine (altretamine), methotrexate, nitrogen mustard, and CCNU (lomustine). Other chemotherapeutic agents under investigation that 10 have shown activity against SCLC include iroplatin, gemcitabine, lonidamine, and taxol. Single-agent chemotherapeutic agents that have not shown activity against SCLC include mitoguazone, mitomycin C, aclarubicin, diaziquone, bisantrene, cytarabine, 15 idarubicin, mitomxantrone, vinblastine, PCNU and esorubicin.

The poor results reported from single-agent chemotherapy has led to use of combination chemotherapy.

Additionally, radiation therapy in conjunction with 20 integrin antagonists and systemic chemotherapy is contemplated to be effective at increasing the response rate for SCLC patients. The typical dosage regimen for radiation therapy ranges from 40 to 55 Gy, in 15 to 30 fractions, 3 to 7 times week. The tissue volume to be 25 irradiated is determined by several factors and generally the hilum and subcarnial nodes, and bilateral mediastinal nodes up to the thoracic inlet are treated, as well as the primary tumor up to 1.5 to 2.0 cm of the margins.

30 Breast Cancer

Today, among women in the United States, breast cancer remains the most frequent diagnosed cancer. One

in 8 women in the United States at risk of developing breast cancer in their lifetime. Age, family history, diet, and genetic factors have been identified as risk factors for breast cancer. Breast cancer is the second 5 leading cause of death among women.

Different chemotherapeutic agents are known in the art for treating breast cancer. Cytotoxic agents used for treating breast cancer include doxorubicin, cyclophosphamide, methotrexate, 5-fluorouracil, 10 mitomycin C, mitoxantrone, taxol, and epirubicin.

(CANCER SURVEYS, Breast Cancer volume 18, Cold Spring Harbor Laboratory Press, 1993).

In the treatment of locally advanced noninflammatory breast cancer, an integrin antagonist 15 and radiation therapy can be used to treat the disease in combination with other antiangiogenic agents, or in combination with surgery, or with chemotherapeutic agents. Preferred combinations of chemotherapeutic agents, and surgery that can be used in combination with 20 the radiation therapy and integrin antagonists include, but are not limited to: 1) doxorubicin, vincristine; 2) cyclophosphamide, doxorubicin, 5-flourouracil, vincristine, prednisone; 3) cyclophosphamide, doxorubicin, 5-flourouracil, premarin, tamoxifen; 4) 25 cyclophosphamide, doxorubicin, 5-flourouracil, premarin, tamoxifen, mastectomy; 5) mastectomy, levamisole; 6) mastectomy; and 7) mastectomy, cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen, halotestin.

In the treatment of locally advanced inflammatory 30 breast cancer, integrin antagonists and radiation therapy can be used to treat the disease in combination with other antiangiogenic agents, or in combination with

surgery, or with chemotherapeutic agents. Preferred combinations of chemotherapeutic agents, radiation therapy and surgery that can be used in combination with the integrin antagonists and radiation include, but are not limited to: 1) cyclophosphamide, doxorubicin, 5-fluorouracil; 2) cyclophosphamide, doxorubicin, 5-fluorouracil, mastectomy; 3) 5-fluorouracil, doxorubicin, cyclophosphamide, vincristine, prednisone, mastectomy; 4) 5-fluorouracil, doxorubicin, cyclophosphamide, vincristine, mastectomy; 5) cyclophosphamide, doxorubicin, 5-fluorouracil, vincristine; 6) cyclophosphamide, doxorubicin, 5-fluorouracil, vincristine, mastectomy; 7) doxorubicin, vincristine, methotrexate, followed by vincristine, cyclophosphamide, 5-fluorouracil; 8) doxorubicin, vincristine, cyclophosphamide, methotrexate, 5-fluorouracil, followed by vincristine, cyclophosphamide, 5-fluorouracil; 9) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, doxorubicin, vincristine, tamoxifen; 10) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, doxorubicin, vincristine, tamoxifen; 11) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, followed by cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, vincristine, tamoxifen; 12) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen,

doxorubicin, vincristine; 13) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, 5 doxorubicin, vincristine, tamoxifen; 14) surgery, followed by cyclophosphamide, methotrexate, 5-fluorouracil, followed by cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, doxorubicin, vincristine; 15) surgery, followed by 10 cyclophosphamide, methotrexate, 5-fluorouracil, prednisone, tamoxifen, followed by cyclophosphamide, methotrexate, 5-fluorouracil, doxorubicin, vincristine; 16) 5-fluorouracil, doxorubicin, cyclophosphamide followed by mastectomy, followed by 5-fluorouracil, 15 doxorubicin, cyclophosphamide.

In the treatment of metastatic breast cancer, radiation therapy and integrin antagonists are used to treat the disease in combination with surgery, or with chemotherapeutic agents. Preferred combinations of 20 chemotherapeutic agents, and surgery that can be used in combination with the radiation therapy and integrin antagonists include, but are not limited to: 1) cyclophosphamide, methotrexate, 5-fluorouracil; 2) cyclophosphamide, adriamycin, 5-fluorouracil; 3) cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone; 4) adriamycin, vincristine; 5) thiotepa, adriamycin, vinblastine; 6) mitomycin, vinblastine; 7) cisplatin, etoposide.

Bladder Cancer

30 The classification of bladder cancer is divided into three main classes: 1) superficial disease, 2) muscle-invasive disease, and 3) metastatic disease.

Currently, transurethral resection (TUR), or segmental resection, account for first line therapy of superficial bladder cancer, i.e., disease confined to the mucosa or the lamina propria. However, intravesical 5 therapies are necessary, for example, for the treatment of high-grade tumors, carcinoma in situ, incomplete resections, recurrences, and multifocal papillary. Recurrence rates range from up to 30 to 80 percent, depending on stage of cancer.

10 Therapies that are currently used as intravesical therapies include chemotherapy, immuontherapy, bacille Calmette-Guerin (BCG) and photodynamic therapy. The main objective of intravesical therapy is twofold: to prevent recurrence in high-risk patients and to treat 15 disease that cannot be resected. The use of intravesical therapies must be balanced with its potentially toxic side effects. Additionally, BCG requires an unimpaired immune system to induce an antitumor effect. Chemotherapeutic agents that are 20 known to be inactive against superficial bladder cancer include Cisplatin, actinomycin D, 5-fluorouracil, bleomycin, and cyclophosphamide methotrxate.

25 In the treatment of superficial bladder cancer, integrin antagonists and radiation therapy are used to treat the disease in combination with surgery (TUR), and intravesical therapies.

Preferred combinations of chemotherapeutic agents are selected from the group consisting of thiotepe (30 to 60 mg/day), mitomycin C (20 to 60 mg/day), and 30 doxorubicin (20 to 80 mg/day).

The preferred intravesicle immunotherapuetic agent that may be used in the present invention is BCG. The

preferred daily dose ranges from 60 to 120 mg, depending on the strain of the live attenuated tuberculosis organism used.

The preferred photodynamic therapeutic agent that 5 may be used with the present invention is Photofrin I, a photosensitizing agent, administered intravenously. It is taken up by the low-density lipoprotein receptors of the tumor cells and is activated by exposure to visible light. Additionally, neodymium YAG laser activation 10 generates large amounts of cytotoxic free radicals and singlet oxygen.

In the treatment of muscle-invasive bladder cancer, radiation therapy and integrin antagonists can be used to treat the disease in combination with other 15 antiangiogenic agents, or in combination with surgery (TUR), intravesical chemotherapy, and radical cystectomy with pelvic lymph node dissection.

The preferred radiation dose is between 5,000 to 7,000 cGY in fractions of 180 to 200 cGY to the tumor. 20 Additionally, 3,500 to 4,700 cGY total dose is administered to the normal bladder and pelvic contents in a four-field technique. Radiation therapy should be considered only if the patient is not a surgical candidate, but may be considered as preoperative 25 therapy.

The preferred combination of chemotherapeutic agents that can be used in combination with radiation therapy and integrin antagonists is cisplatin, methotrexate, vinblastine.

30 Currently no curative therapy exists for metastatic bladder cancer. The present invention contemplates an effective treatment of bladder cancer leading to

improved tumor inhibition or regression, as compared to current therapies.

In the treatment of metastatic bladder cancer, a combination of radiation therapy and integrin 5 antagonists can be used to treat the disease in combination with surgery, or with chemotherapeutic agents.

Preferred combinations of chemotherapeutic agents include, but are not limited to: 1) cisplatin and 10 methotrexate; 2) doxorubicin, vinblastine, cyclophosphamide, and 5-fluorouracil; 3) vinblastine, doxorubicin, cisplatin, methotrexate; 4) vinblastine, cisplatin, methotrexate; 5) cyclophosphamide, doxorubicin, cisplatin; 6) 5-fluorouracil, cisplatin.

15 Head and Neck Cancers

Head and neck cancer accounts for approximately 2% of new cancer cases in the United States. Common intracranial neoplasms include glioma, meningioma, neurinoma, and adenoma. Preferred combinations that 20 can be used along with a combination of radiation therapy and an integrin antagonist for the treatment of malignant glioma include: 1) BCNU (carmustine); 2) methyl CCNU (lomustine); 3) medrol; 4) procarbazine; 5) BCNU, medrol; 6) misonidazole, BCNU; 7) streptozotocin; 25 8) BCNU, procarbazine; 9) BCNU, hydroxyurea, procarbazine, VM-26; 10) BNCU, 5-flourouacil; 11) methyl CCNU, dacarbazine; 12) misonidazole, BCNU; and 13) PCNU. The preferred dose of radiation therapy is about 5,500 to about 6,000 cGY. Preferred radiosensitizers include 30 misonidazole, intra-arterial Budr and intravenous iododeoxyuridine (IUDR).

Biological Evaluation

Solitary tumors are generated in the right hind legs of mice by the injection of 3×10^5 viable NFSA tumor cells. Treatment with an integrin antagonist (6 mg/kg body weight) or vehicle (0.05% Tween 20 and 0.95% polyethylene glycol) given in the drinking water is started when tumors are approximately 6 mm in diameter and the treatment is continued for 10 consecutive days. Water bottles are changed every 3 days. Tumor

10 irradiation is performed 3-8 days after initiation of the treatment with an integrin antagonist. The end points of the treatment are tumor growth delay (days) and TCD_{50} (tumor control dose 50, defined as the radiation dose yielding local tumor cure in 50% of

15 irradiated mice 120 days after irradiation). To obtain tumor growth curves, three mutually orthogonal diameters of tumors are measured daily with a vernier caliper, and the mean values are calculated.

Local tumor irradiation with single γ -ray doses of 20 30, 40, or 50 Gy is given when these tumors reach 8 mm in diameter. Irradiation to the tumor is delivered from a dual-source ^{137}Cs irradiator at a dose rate of 6.31 Gy/minute. During irradiation, unanesthetized mice are immobilized on a jig and the tumor is centered in a 25 circular radiation field 3 cm in diameter. Regression and regrowth of tumors are followed at 1-3 day intervals until the tumor diameter reaches approximately 14 mm.


What is claimed is:

1. A method for treating neoplasia in a subject in need of such treatment, the method comprises treating the subject with radiation therapy and a therapeutically effective amount of an integrin antagonist or pharmaceutically-acceptable salt thereof.

2. The method of Claim 1 wherein the neoplasia is selected from lung cancer, breast cancer, gastrointestinal cancer, bladder cancer, head and neck cancer and cervical cancer.


3. A method for treating neoplasia in a subject in need of such treatment, the method comprises treating the subject with radiation therapy and a therapeutically effective amount of a integrin antagonist or pharmaceutically-acceptable or derivative thereof, wherein the integrin antagonist is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of:

1)



25 (3R)-N-[(5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl)glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine;


2)



(3R)-N-[1,6-dihydro-6-oxo-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]-3-pyridinyl]carbonyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-β-alanine;

5

3)



10

(3R)-N-[3-amino-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-β-alanine;

4)


15



(3R)-N-[3-[(hydroxyamino)carbonyl]-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-β-alanine;

20

5)




5

(3R)-N-[3-[(4-, 5-dihydro-1H-imidazol-2-yl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

10


6)



(3R)-N-[3-[(aminoiminomethyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;

15


7)



20

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-b-alanine;


8)



5

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3,5-dichloro-2-hydroxyphenyl)-D-alanine;

9)




10

(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(5-bromo-3-chloro-2-hydroxyphenyl)-D-alanine;

15


10)



20


(3R)-N-[3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoyl]glycyl-3-(3-bromo-5-chloro-2-hydroxyphenyl)-D-alanine;

11)



5 b-[3-[[3-[[4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]sulfonyl]amino]phenyl]-3,5-difluorobenzenepropanoic acid;


12)




10 3,5-difluoro-b-[3-[[3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl]amino]methyl]phenyl]benzenepropanoic acid;

15

13)




14)



(2E)-3-[3-ethyl-4-[(3-[(1,4,5,6-tetrahydro-2-pyrimidinyl)amino]benzoyl)amino]phenyl]-2-propenoic acid;

5


15)



10

(2E)-3-[2-[3-[(4,5-dihydro-1H-imidazol-2-yl)amino]phenyl]-2-oxoethoxy]phenyl]-2-propenoic acid;

16)




15

(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid;


17)

20




25

5 18)




(2S)-2,3,4,5-tetrahydro-4-methyl-7-[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-
10 benzodiazepine-2-acetic acid;

19)




(bR)-b-[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-
15 pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid;

20 20)



21)



5



22)

10

23)



24)

15


Vitaxin antibody (Ixsys);

25)

20


Merck KGaA EMD-121974, cyclo[RGDf-N(Me)V-];

26)




27)

5




28)




29)


10



30)




31)




5

32)




33)




10

34)




35)




15

36)




37)




5

38)




39)




10

40)




41)




5

42)




43)



10


4. A method for treating neoplasia in a subject
in need of such treatment, the method comprises
treating the subject with radiation therapy and a
therapeutically effective amount of a integrin
antagonist or pharmaceutically-acceptable or
derivative thereof, wherein the integrin antagonist
is selected from compounds, and their
pharmaceutically acceptable salts, of the group
consisting of:

1)



(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid;


2)



(2S)-7-[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;

15


3)



20


(2S)-2,3,4,5-tetrahydro-4-methyl-7-[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;

4)




5 (bR)-b-[[[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid;

5)




10

6)




15

7)



8)



5

9)


Vitaxin antibody (Ixsys);

10)

10


Merck KGaA EMD-121974, cyclo[RGDF-N(Me)V-];

11)




12)


15



13)




14)




15)

5




5. The method of Claim 4 wherein the integrin antagonist is



10

(10S)-10,11-dihydro-3-[3-(2-pyridinylamino)propoxy]-5H-dibenzo[a,d]cycloheptene-10-acetic acid.

15 6. The method of Claim 4 wherein the integrin antagonist is




20

(2S)-7-[(1H-benzimidazol-2-ylmethyl)methylamino]carbonyl]-2,3,4,5-

tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid.


7. The method of Claim 4 wherein the integrin antagonist is



(2S)-2,3,4,5-tetrahydro-4-methyl-7-[(5-methyl-1H-imidazo[4,5-b]pyridin-2-yl)methyl]amino]carbonyl]-3-oxo-1H-1,4-benzodiazepine-2-acetic acid.


10

8. The method of Claim 4 wherein the integrin antagonist is



15 (bR)-b-[(3R)-2-oxo-3-[2-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl]acetyl]amino]-1H-indole-3-pentanoic acid.


20 9. The method of Claim 4 wherein the integrin antagonist is




10. The method of Claim 4 wherein the integrin antagonist is Vitaxin antibody(Ixsys).

5 11. The method of Claim 4 wherein the integrin antagonist is Merck KGaA EMD-121974, cyclo[RGDf-N(Me)V-].


10 12. The method of Claim 4 wherein the integrin antagonist is




15 13. The method of Claim 4 wherein the integrin antagonist is



20 14. The method of Claim 4 wherein the integrin antagonist is



15. The method of Claim 4 wherein the integrin antagonist is



5

16. A combination comprising radiation therapy and a therapeutically effective amount of an integrin antagonist or a pharmaceutically-acceptable salt thereof.

10

17. The method of Claim 1 wherein the combination is administered a sequential manner.

18. The method of Claim 1 wherein the combination
15 is administered in a substantially simultaneous manner.

19. The method of Claim 3 wherein the combination is administered a sequential manner.

20. The method of Claim 3 wherein the combination
is administered in a substantially simultaneous manner.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 July 2000 (06.07.2000)

PCT

(10) International Publication Number
WO 00/38715 A3

(51) International Patent Classification⁷: A61K 41/00, A61P 35/00

(74) Agents: KEANE, J. Timothy et al.; G.D. Searle & Co., Corporate Patent Department, P.O. Box 5110, Chicago, IL 60680-5110 (US).

(21) International Application Number: PCT/US99/30621

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 22 December 1999 (22.12.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/113,786 23 December 1998 (23.12.1998) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): MCKEARN, John, P. [US/US]; 18612 Babler Meadows Drive, Glencoe, MO 63038 (US). GORDON, Gary [US/US]; 3282 University Avenue, Highland, IL 60035 (US). CUNNINGHAM, James, J. [CA/US]; 3733 North Bell Avenue, Chicago, IL 60618 (US). GATELY, Stephen, T. [CA/US]; 357 E. Shady Pines Court, Palatine, IL 60067-8800 (US). KOKI, Alane, T. [US/US]; 6689 Highway 185, Beaufort, MO 63013 (US). MASFERRE, Jaime, L. [CL/US]; 1213 Blairshire, Ballwin, MO 63011 (US).

Published:

— With international search report.

(88) Date of publication of the international search report:
4 January 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 00/38715 A3

(54) Title: USE OF AN INTEGRIN ANTAGONIST AND RADIATION IN THE TREATMENT OF NEOPLASIA

(57) Abstract: The present invention provides methods to treat neoplasia disorders in a mammal using a combination of radiation and an integrin antagonist.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30621

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K41/00 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 31359 A (DUGGAN MARK E ;MERCK & CO INC (US)) 23 July 1998 (1998-07-23) cited in the application claims 21-25 page 20, line 14-21	1,2, 16-20
Y	---	1-3, 16-20
Y	WO 98 14192 A (COUSINS RUSSELL DONOVAN ;SMITHKLINE BEECHAM CORP (US); KWON CHET () 9 April 1998 (1998-04-09) cited in the application page 6, line 12-24,33-35	1-3, 16-20
Y	WO 97 41844 A (ALCON LAB INC ;DOSHI RUPA (US); CLARK ABBOT F (US)) 13 November 1997 (1997-11-13) page 5-6; table 5 ---	1-3, 16-20
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

28 April 2000

Date of mailing of the international search report

19.07.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/30621

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 99 31099 A (HUTCHINSON JOHN H ;MEISSNER ROBERT S (US); ASKEW BEN C (US); DUGGA) 24 June 1999 (1999-06-24) cited in the application claims 1,44 ---	1-3, 16-20
P,Y	WO 99 52896 A (CHANDRAKUMAR NIZAL SAMUEL ;DESAI BIPINCHANDRA NANUBHAI (US); DEVAD) 21 October 1999 (1999-10-21) abstract -----	1-3, 16-20

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 99/30621

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1 - 2, 16 - 20 (all partly), 3.1-3.10

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

The present claims relate to an extremely large number of possible methods and combinations. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the methods and combinations claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the methods and combinations referring to the general concept of the application, i.e. the combined use of integrin antagonists as defined in the dependent claims and radiation for the treatment or prevention of neoplasia.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-2,16-20 (all partly), 3.1-3.10

Use of radiation therapy together with the structurally related integrin antagonists as defined in claims 3.1-3.10 in the treatment of neoplasia

2. Claims: 1-2,16-20 (all partly), 3.11-3.12

Use of radiation therapy together with the structurally related integrin antagonists as defined in claims 3.11-3.12 in the treatment of neoplasia

3. Claims: 1-2,16-20 (all partly), 3.13

Use of radiation therapy together with the integrin antagonist as defined in claim 3.13 in the treatment of neoplasia

4. Claims: 1-2,16-20 (all partly), 3.14

Use of radiation therapy together with the integrin antagonist as defined in claim 3.14 in the treatment of neoplasia

5. Claims: 1-2,16-20 (all partly), 3.15

Use of radiation therapy together with the integrin antagonist as defined in claim 3.15 in the treatment of neoplasia

6. Claims: 1-2,16-20 (all partly), 3.16,5

Use of radiation therapy together with the integrin antagonist as defined in claims 3.16, 5 in the treatment of neoplasia

7. Claims: 1-2,16-20 (all partly), 3.17-3.18,3.35,4.1-4.3, 4.14,6,7,14s

Use of radiation therapy together with the structurally related integrin antagonists as defined in claims 3.17-3.18,3.35,4.1-4.3, 4.14, 6,7,14 in the treatment of neoplasia

8. Claims: 1-2,16-20 (all partly), 3.19,8

Use of radiation therapy together with the integrin

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

antagonist as defined in claims 3.19, 8 in the treatment of neoplasia

9. Claims: 1-2,16-20 (all partly), 3.20-3.22,4.5-4-7

Use of radiation therapy together with the structurally related integrin antagonists as defined in claims 3.20-3.22, 4.5-4.7 in the treatment of neoplasia

10. Claims: 1-2,16-20 (all partly), 3.23, 4.8, 9

Use of radiation therapy together with the integrin antagonist as defined in claims 3.23, 4.8, 9 in the treatment of neoplasia

11. Claims: 1-2,16-20 (all partly), 3.24,4.8, 10

Use of radiation therapy together with the integrin antagonist as defined in claims 3.24, 4.8, 10 (vitaxin antibody (Ixsys)) in the treatment of neoplasia

12. Claims: 1-2,16-20 (all partly), 3.25,4.9,11

Use of radiation therapy together with the integrin antagonist as defined in claims 3.25, 4.9,11 (MERCK KGaA EMD-121974) in the treatment of neoplasia

13. Claims: 1-2,16-20 (all partly), 3.26, 4.11,

Use of radiation therapy together with the integrin antagonist as defined in claims 3.26, 4.11 in the treatment of neoplasia

14. Claims: 1-2,16-20 (all partly), 3.27, 4.12, 12

Use of radiation therapy together with the integrin antagonist as defined in claims 3.27, 4.12, 12 in the treatment of neoplasia

15. Claims: 1-2,16-20 (all partly), 3.28

Use of radiation therapy together with the integrin antagonist as defined in claim 3.28 in the treatment of neoplasia

16. Claims: 1-2,16-20 (all partly), 3.29

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Use of radiation therapy together with the integrin antagonist as defined in claim 3.29 in the treatment of neoplasia

17. Claims: 1-2,16-20 (all partly), 3.30

Use of radiation therapy together with the integrin antagonist as defined in claim 3.30 in the treatment of neoplasia

18. Claims: 1-2,16-20 (all partly), 3.31,4.4

Use of radiation therapy together with the integrin antagonist as defined in claims 3.31 and 4.4 in the treatment of neoplasia

19. Claims: 1-2,16-20 (all partly), 3.32

Use of radiation therapy together with the integrin antagonist as defined in claim 3.32 for the treatment of neoplasia

20. Claims: 1-2,16-20 (all partly), 3.33

Use of radiation therapy together with the integrin antagonist as defined in claim 3.33 for the treatment of neoplasia

21. Claims: 1-2,16-20 (all partly), 3.34, 4.13, 13

Use of radiation therapy together with the integrin antagonist as defined in claims 3.34, 4.13, 13 for the treatment of neoplasia

22. Claims: 1-2,16-20 (all partly), 3.37-3.41

Use of radiation therapy together with the structurally related integrin antagonists as defined in claims 3.37-3.41,16 for the treatment of neoplasia

23. Claims: 1-2,16-20 (all partly), 3.42

Use of radiation therapy together with the integrin antagonist as defined in claim 3.42 for the treatment of neoplasia

24. Claims: 1-2,16-20 (all partly), 3.43

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Use of radiation therapy together with the integrin antagonist as defined in claim 3.43 for the treatment of neoplasia

25. Claims: 1-2,16-20 (all partly), 3.36,4.15,15

Use of radiation therapy together with the integrin antagonist as defined in claims 3.36, 4.15, 15 for the treatment of neoplasia

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/30621

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9831359	A 23-07-1998	AU 6023198	A	07-08-1998
		EP 1007026	A	14-06-2000
WO 9814192	A 09-04-1998	AU 4746297	A	24-04-1998
		BG 103299	A	31-01-2000
		CN 1238689	A	15-12-1999
		EP 0957917	A	24-11-1999
		HU 9903769	A	28-03-2000
		NO 991590	A	31-05-1999
		PL 332674	A	27-09-1999
		SK 42599	A	10-12-1999
WO 9741844	A 13-11-1997	AU 2438297	A	26-11-1997
WO 9931099	A 24-06-1999	AU 1725799	A	05-07-1999
		AU 1914499	A	05-07-1999
		WO 9930709	A	24-06-1999
WO 9952896	A 21-10-1999	AU 3449999	A	01-11-1999